|
|
 |
 |
 |
|
|
|||
|
||||
|
||||
Obesity - Cancer Link?From: art fougner, md (evsono@pipeline.com)Tue Jul 20 07:33:03 2004
Leptin is an important marker in gynecologic and breast cancers Prognostics July 20, 2004 2004 JUL 20 - (NewsRx.com & NewsRx.net) -- Increased leptin levels are prognostic of gynecologic and breast cancers, according to a study from Italy. "Leptin is a hormone involved in the regulation of body weight and sexual maturation. We previously reported that cancer cachexia was associated with reduced or normal levels of leptin. Here we investigate whether leptin levels are related to cachetic or hormonal status," wrote L. Tessitore and associates in the International Journal of Oncology. "Circulating leptin and its mRNA from adipose tissue were measured in 87 patients with gynecological and breast cancers and related to turnout, cachexia, and hormonal markers. We found that leptin protein increased in patients with these tumors due to higher mRNA levels," they said (Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. Int J Oncol, 2004;24(6):1529-1535). "In patients with ovarian cancer," the researchers noted, "the increased leptin levels were associated with higher circulating follicle-stimulating hormone (FSH). The higher leptin concentrations in patients with endometrial and portio tumors were related to an increase in tissue estrogen receptor (ER) and progesterone receptor (PGR) and, only in the postmenopause, to an increase in circulating estradiol." Additionally, the scientists reported, "Patients with breast cancer showed enhanced blood plasma concentrations of progesterone and estradiol, and enhanced tissue levels of ER and PGR associated with increased leptin levels." Tessitore and colleagues concluded, "The data from the present study indicate that, in gynecological and breast cancers, leptin is related to hormonal status but not to cachexia. "We suggest that leptin stimulates the production of sexual hormones, important risk factors for these tumors, and we propose leptin as a novel prognostic marker." For additional information, contact L. Tessitore, University Piemonte Orientale Amedeo Avogadro, Dipartimento Science Chim Alimentari Farmaceut & Farm, C So Ferrucci 33, I-28100 Novara, Italy. The publisher of the International Journal of Oncology can be contacted at: Professor D a Spandidos, 1, S Merkouri St., Editorial Office, Athens 116 35, Greece. The information in this article comes under the major subject areas of Prognostic Indicators, Breast Cancer, Gynecologic Cancer, Oncology, and Women's Health. This article was prepared by Cancer Weekly editors from staff and other reports. Copyright 2004, Cancer Weekly via NewsRx.com & NewsRx.net. ©Copyright 2004, Women's Health Weekly via NewsRx.com & NewsRx.net http://www.obgyn.net/newsheadlines/womens_health-Prognostics-20040720-62.asp art
-- art fougner, md ich bin ein New Yorker
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Wed Jul 2 04:37:36 2008 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.